Alzheimer's Blood Tests: A New Era Dawns

Australians can now access new blood tests for Alzheimer's disease, marking a significant advancement in diagnosis. The Therapeutic Goods Administration has approved these tests for clinical use.

These innovations offer a simpler and more accessible method for detecting Alzheimer's, the most common form of dementia. Previously, confirmation often required expensive PET scans or invasive lumbar punctures.

Researchers have developed blood tests capable of accurately measuring biomarkers, such as the pTau217 protein, which are indicative of Alzheimer's-related brain changes. While not a standalone diagnostic tool, these tests, along with pTau181 and APOE ε4 gene variant analysis, aid clinicians.

The Asia-Pacific Centre of Excellence for Alzheimer's Disease Diagnosis has opened at Neuroscience Research Australia in Sydney. This centre aims to support future Medicare funding and develop national guidelines for biomarker use.

Currently, these blood biomarker tests are most suitable for individuals experiencing cognitive symptoms or mild cognitive impairment, not for routine screening of healthy adults. They are considered an important adjunct to clinical assessment and emerging disease-modifying therapies.

These tests are not yet covered by Medicare, meaning patients may incur out-of-pocket expenses. The goal is to expedite dementia diagnosis, which in Australia can involve lengthy delays, and integrate these advancements with emerging treatments.